|
|
|
Vol. 12, No. 13, pp. 1975-1985, July 1, 1998
Center for Advanced Biotechnology and Medicine, Cancer Institute of New Jersey, Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, New Jersey 08854 USA
| |
Abstract |
|---|
|
|
|---|
The p53 tumor suppressor gene product interacts with the p300 transcriptional coactivator that regulates the transactivation of p53-inducible genes. The adenovirus E1A protein has been shown to bind to p300 and inhibit its function. E1A inhibits p53 transactivation and also promotes p53 accumulation by a p300-dependent mechanism. Murine double minute 2 (Mdm2) is a transcriptional target of p53 that binds to p53 and inhibits its transcriptional activity. E1A inhibited mdm2 transactivation without affecting the expression of p21WAF1 or Bax, which resulted in high levels of p53 accumulation and apoptosis. Ectopic expression of p300 restored Mdm2 levels and inhibited p53-dependent apoptosis, as did ectopic expression of Mdm2. Thus, p300 is required for mdm2 induction by p53 and the subsequent inhibition of p53 stabilization. Inhibition of p300 by E1A results in stabilization of p53 and causes apoptosis. Moreover, E1B 19K or Bcl-2 expression in E1A-transformed cells abrogated p53-dependent apoptosis by restoring mdm2 transactivation by p53. Hence, p300 regulation of mdm2 expression controls apoptotic activity of p53, and 19K or Bcl-2 bypass E1A inhibition of p300 transactivation of Mdm2.
[Key Words: p53; Mdm2; p300; apoptosis; Bcl-2; E1B 19K; E1A; transcription]
| |
Introduction |
|---|
|
|
|---|
The tumor suppressor p53 gene product is a negative regulator of
cellular growth and transformation (Vogelstein and Kinzler 1992
; Ko and
Prives 1996
; Levine 1997
; White 1996
). Many studies have demonstrated that p53 functions as a transcriptional regulator by
sequence-specific DNA binding (El-Deiry et al. 1992
; Funk et al. 1992
;
Pietenpol et al. 1994
). The p53 gene product regulates transcription by
activation or repression (Ko and Prives 1996
). Studies have shown that
DNA damage increases p53 levels, which promotes cell cycle arrest
allowing DNA repair to occur, or it induces apoptosis, presumably when
damage is beyond repair (Ko and Prives 1996
; White 1996
; Levine 1997
).
The growth arrest function of p53 is implemented predominantly by
transactivation of the cyclin-dependent kinase inhibitor
p21/WAF1/CIP1 (El-Deiry et al. 1993
) and p53 can induce apoptosis by up-regulating the death-promoting bax gene (Miyashita and Reed 1995
). Other transcriptional
targets for p53 include GADD45 (Kastan et al. 1992
), murine
double minute 2 (mdm2) (Barak et al. 1993
; Wu et al. 1993
), cyclin
G (Okamoto and Beach 1994
), and IGF-BP3 (Buckbinder et al.
1995
). The DNA-binding ability of p53 appears to be important because
the most frequently occurring p53 mutations in human tumors are found
in this domain (Hollstein et al. 1991
; Ko and Prives 1996
). Hence, intact p53 transcriptional function is important to maintain genomic integrity.
The mdm2 gene was originally cloned because of its
amplification in a spontaneously transformed murine
BALB/c cell line (Fakharzadeh et al. 1991
). The human
homolog of Mdm2 protein was shown to be a negative regulator of p53.
Mdm2 protein inhibits p53-mediated functions of G1 arrest and
apoptosis (Chen et al. 1996a
), most likely by binding to the
amino-terminal transactivation domain of p53 (Momand et al. 1992
;
Oliner et al. 1993
). Furthermore, Mdm2 appears to direct p53
degradation via the ubiquitin pathway (Haupt et al. 1997
; Kubbutat et
al. 1997
). The mdm2 promoter contains p53 binding consensus
sequences in which p53 binds and positively regulates its expression,
creating a negative feedback loop for regulating the activity and
levels of p53 (Barak et al. 1993
; Haupt et al. 1996
; Wu et al. 1993
).
The functional interdependence of Mdm2 and p53 was exemplified in
studies with knockout mice. Loss of Mdm2 resulted in early embryonic
lethality, which was rescued by deletion of p53 (Donehower et al. 1992
;
Montes de Oca Luna et al. 1995
). Thus, Mdm2 is required in vivo for
down-modulation of p53 function and perturbation of this regulation can
be deleterious to embryonic development.
The CBP/p300 family members regulate transcription by
functioning as transcriptional coactivators. Although the precise
mechanism of transcriptional adaptor function is not known,
CBP/p300 and an interacting protein, P/CAF,
have been shown to have histone acetyltransferase activity (Bannister
and Kouzarides 1996
; Ogryzko et al. 1996
; Yang et al. 1996
),
implicating a role for histone acetylation in transcriptional
regulation. These proteins also interact with several transcription
factors such as the TAFs (Thut et al. 1995
), TBP (Abraham et al. 1993
),
CREB (Chrivia et al. 1993
; Kwok et al. 1994
), c-Jun/v-Jun
(Bannister and Kouzarides 1995
), c-Myb/v-Myb (Dai et al.
1996
), c-Fos (Bannister and Kouzarides 1995
), and others, which may
determine the specificity of the regulation. The p300 family of
proteins has been shown recently to bind to p53 and function as
coactivators of p53-inducible genes (Avantaggiati et al. 1997
; Gu et
al. 1997
; Lill et al. 1997
; Scolnick et al. 1997
). The amino-terminal
activation domain of p53 interacts directly with the carboxy-terminal
of p300 (Gu and Roeder 1997
). It has also been shown that p300 can
acetylate the carboxy-terminal domain of p53 and that this modification
increases the sequence-specific DNA-binding ability of p53 (Gu and
Roeder 1997
). Thus, acetylation of specific transcription factors may
reflect one level of p300 transcriptional regulation.
The adenoviral early region 1 (E1) genes encode for proteins that aid
in cellular transformation by activating proliferation and suppressing
apoptosis (White 1993
; White and Gooding 1994
). Expression of the
adenoviral E1A gene stimulates cell cycle progression by interacting
with and subverting the function of cellular proteins required for
normal cell cycle and transcription regulation. E1A interacts with the
retinobalstoma (Rb) gene product as well as its family members, p107
and p130 (Dyson and Harlow 1992
; Moran 1993
; Whyte et al. 1988
). E1A
also binds to and sequesters p300 (Moran 1993
; Eckner et al. 1994
; Yang
et al. 1996
). E1A interactions with these cellular proteins are
important for transformation as suggested by the fact that E1A mutants
that fail to interact with these proteins are incapable of promoting
transformation. Expression of E1A alone, however, is insufficient to
transform primary baby rat kidney (BRK) cells because cell cycle
deregulation by E1A also stimulates p53-dependent apoptosis. Binding of
p300 to E1A cosegregates with induction of p53 and stabilization
(Sanchez-Prieto et al. 1995
; Chiou and White 1997
; Querido et al.
1997
). Transcriptional activation of p53 target genes, such as
bax (Han et al. 1996
), followed by induction of caspase
activation implements cell death (Rao and White 1997
; Sabbatini et al.
1997
). Transcriptional activation of the p53 target gene
p21WAF1 is also induced, which contributes to
implementation of cell cycle arrest by p53, which is not apparent
because of cell death (Sabbatini et al. 1995a
,b
; Han et al. 1996
).
E1A-induced cellular transformation is sustained by coexpression of the
Bcl-2 adenoviral homolog, E1B 19K or Bcl-2 itself, which inhibit
E1A-induced, p53-mediated apoptosis. E1B 19K and Bcl-2 inhibit
apoptosis in part by binding to the death-promoting Bax protein (Han et
al. 1996
). Thus E1B 19K or Bcl-2 expression inhibits p53-mediated
apoptosis but not growth arrest (Debbas and White 1993
; Chiou et al.
1994b
; Sabbatini et al. 1995a
; Han et al. 1996
). These co-operative
functions between early adenoviral genes stimulating cell cycle
progression and inhibiting apoptosis ensures efficient transformation.
We report that p300 is required specifically for transactivation of the mdm2 gene by p53 and for regulating p53-mediated apoptosis. Cells expressing E1A were unable to up-regulate Mdm2, causing stabilization of high levels of p53 that resulted in p53-dependent apoptosis. In contrast, BRK cells expressing c-Myc instead of E1A, up-regulated Mdm2, causing inhibition of p53 stabilization and inhibition of p53-dependent apoptosis. Thus, the inabilty to down-regulate p53 is associated with apoptosis and may explain the differences between the p53-dependent apoptotic response of E1A versus Myc transformed cells. Furthermore, E1B 19K or Bcl-2 expression restores mdm2 transactivation at the level of mRNA, bypassing the requirement for p300 cotransactivation. Thus the Bcl-2 family members may regulate the specificity of p53-dependent target gene activation and thereby contribute to inhibition of p53-dependent apoptosis.
| |
Results |
|---|
|
|
|---|
Mdm2 expression regulates p53-dependent apoptosis in BRK cells
BRK cells were transformed by a temperature-sensitive p53 (val135)
mutant and either adenovirus E1A (p53A) or c-Myc (LTR.1A). As
previously reported, both types of cell lines expressed the temperature-sensitive p53 (val135) mutant in which p53 is in the wild-type conformation at the permissive temperature of 32°C and in
the mutant conformation at the nonpermissive temperature of 37.5°C
(Debbas and White 1993
; Sakamuro et al. 1995
). There are two striking
differences between E1A + tsp53 (val135)-transformed (p53A) and
myc + tsp53 (val135)-transformed (LTR.1A) cell lines. First, BRK
cells expressing E1A undergo massive apoptosis at the permissive
temperature (Debbas and White 1993
; Chiou et al. 1994a
; Sabbatini et
al. 1995a
,b
), whereas the Myc-expressing cells undergo a wave of
apoptosis within the first 24 hr at the permissive temperature but are
predominantly resistant to apoptosis (Sakamuro et al. 1995
). Second,
E1A-expressing cells maintain high levels of p53, whereas p53 levels
are low at 32°C in Myc-expressing cells (Debbas and White 1993
;
Sakamuro et al. 1995
). Thus, high levels of p53 correlate with
augmentation of the apoptotic response in E1A-expressing p53A cells.
Because E1A stabilizes p53 (Lowe and Ruley 1993
; Chiou et al. 1994b
)
and this activity requires that E1A binds to p300 (Chiou and White
1997
), this suggests a possible function for sequestration of p300 and
induction of p53 levels. Furthermore, recent reports demonstrate the
requirement for p300 in p53 transactivation (Gu et al. 1997
; Lill et
al. 1997
; Scolnick et al. 1997
) and a role for Mdm2 in promoting p53
degradation (Haupt et al. 1997
; Kubbutat et al. 1997
). We therefore
investigated the possible role of p300 in the Mdm2-dependent
negative-feedback loop and the control of p53-dependent apoptosis.
First, we determined whether the levels of p53-inducible gene products
Mdm2, p21WAF1, and Bax were affected by the p300-binding
protein E1A. Western blot analysis shows that high levels of p53 were
stabilized in E1A-transformed cells and not stabilized in
Myc-transformed cells at 32°C (Fig. 1A) as reported previously
(Debbas and White 1993
; Sakamuro et al. 1995
). A
lower band that may represent a proteolytic cleavage product of p53 was
also observed in p53A cells as apoptosis progressed at the permissive
temperature (Fig. 1A). High p53 levels correlated with apoptosis in
p53A cells (Fig. 1, C, top, and D, top). Endogenous Mdm2 protein was
initially present but was down-regulated at 32°C in p53A cells as
shown by Western blot analysis (Fig. 1A) and immunofluorescence (Fig.
1B, top). Western blot analysis of Mdm2 in p53A cells at the permissive
temperature showed a lower band at ~50 kD, recognized specifically
by the anti-Mdm2 monoclonal antibody (data not shown). This lower band
may represent a cleavage product of Mdm2. However, this band
disappeared as cells were incubated at the permissive temperature. Our
studies did not investigate Mdm2 cleavage in apoptosis, however, we
cannot rule out the possibility that Mdm2 cleavage may play a role in
the regulation of apoptosis. Mdm2 down-regulation was surprising
because mdm2 is a p53-regulated gene and suggested that p300
may be necessary for Mdm2 transactivation by p53.
|
In c-Myc-transformed LTR.1A cells, Mdm2 was up-regulated and p53 levels were low at 32°C (Fig. 1A,B, bottom). Therefore Myc- but not E1A-expressing BRK cells demonstrate p53-dependent induction of mdm2. Furthermore, high levels of Mdm2 in Myc-transformed BRK cells may have promoted p53 degradation (Fig. 1A). The LTR.1A cells initially undergo apoptosis but rapidly become resistant to p53-mediated cell death at 32°C (Fig. 1C, bottom, and 1D, bottom), which correlated with the low levels of p53 and up-regulation of Mdm2. Western blot analysis also showed an increase in the 50-kD lower band detected specifically by the anti-Mdm2 antibody (data not shown). Hence, the lower band that may represent Mdm2 cleavage product was also present in cells that were resistant to apoptosis. The decrease in Mdm2 levels observed in cells maintained at the restrictive temperature may be because of the confluency of the cells. At the restrictive temperature the BRK cell lines are proliferating and reach confluence in 2-3 days in this assay.
Mdm2 is only one of many p53-inducible genes that collectively act to
modulate the physiological response to p53 induction. Therefore,
p21WAF1 and Bax levels were also examined for transactivation
in p53A and LTR.1A cells. In p53A cells, Bax and p21WAF1
levels were induced at 32°C even in the presence of E1A and
inhibition of p300 (Fig. 1A) (Sabbatini et al. 1995b
; Han et al. 1996
).
LTR.1A cells down-regulated Bax but up-regulated low levels of
p21WAF1 at 32°C (Fig. 1A). We do not know why Bax is also
present in LTR.1A cells at the restrictive temperature, but this
suggests that Bax may require an activation step to induce cell death. Similar results (data not shown) were obtained with independent E1A + tsp53 (val135)-transformed and c-Myc + tsp53
(val135)-transformed clones (Debbas and White 1993
; Sakamuro et al.
1995
). These results indicate that E1A and Myc alter p53-dependent gene
expression differentially.
To determine whether the absence of Mdm2 protein in p53A cells
reflected a transcriptional event, we performed Northern blot analysis
using cytoplasmic RNA extracted from E1A-transformed p53A cells
incubated at the permissive temperature for the indicated time
intervals (Fig. 1E). Two transcripts (3.3 and 1.7 kb) hybridized to an
mdm2-specific probe. Both transcripts, particularly the 3.3 kb, were down-regulated to some extent as cells were incubated at
32°C. The detection of mdm2 mRNA in p53A cells was
difficult because mdm2 expression was very low to begin with
and was not induced by wild-type p53. Induction of mdm2 mRNA
by p53, however, was observed in BRK cell lines expressing E1B 19K (see
below). In contrast, we have previously reported that Bax and
p21WAF1 mRNAs were up-regulated transiently in p53A
cells incubated at the permissive temperature within the same time
interval analyzed here for mdm2 mRNA expression (Sabbatini et
al. 1995a
,b
; Han et al. 1996
). Attempts to examine mdm2 mRNA
levels at later times failed as the RNA in p53A cells became degraded
as most of the cells became apoptotic. Therefore, E1A, although
preventing mdm2 expression, did not affect p53's ability to
transactivate Bax and p21WAF1. These
results suggest that p300 may be required for Mdm2 transactivation, but
may be dispensable for Bax and p21WAF1 regulation.
p300 is required for the up-regulation of Mdm2 by p53 and inhibition of p53-mediated apoptosis
We next attempted to rescue p53A cells from apoptosis at the
permissive temperature by ectopically expressing p300. Vector alone,
wild-type p300, and a functional but truncated form of p300 with a
deletion of E1A-binding domain (Arany et al. 1994
) were transiently
transfected in p53A cells. p53-dependent apoptosis was examined at the
permissive temperature 48 hr post-transfection. p53A cells transiently
expressed the exogenous wild-type p300 and the E1A-binding mutant form
of p300, neither of which were detected in mock transfected cells (Fig.
2A,B). The up-regulation of Mdm2 in p300-transfected
cells was not detected by Western blot analysis above endogenous levels
(Fig. 2A) because the transfection efficiency was low in transient
assays. However, the up-regulation of Mdm2 in both wild-type and
E1A-binding mutant of p300 was easily observed in 90% of transfected
cells by indirect immunofluorescence when individual transfected cells
were examined (Fig. 2B, arrows). Furthermore, ectopic expression of
wild-type and mutant p300 rescued cells from apoptosis as cell
viability was elevated as much as 20%-40% above mock-transfected
cells (Fig. 2C). The mutant form of p300, which was unable to bind E1A,
protected cells better than wild-type p300, presumably because it can
evade E1A sequestration. In addition, we determined the percentage of
cells with apoptotic morphology that were expressing wild-type p300
ectopically or the E1A-binding mutant of p300 following transient
transfection with 24 µg of plasmid DNA. Apoptotic morphology was
determined by counting cells that were rounded in shape and detaching
from the dish. The percentage of cells with apoptotic morphology
transiently expressing a control protein, a fragment of the lamin A
protein (Rao et al. 1996
), compared to p300 and mutant p300 transfected p53A cells at the permissive temperature was determined by indirect immunofluorescence (Fig. 2D). Only 4%-8% of the cells expressing wild-type p300 and mutant p300, respectively, have apoptotic
morphology compared to 62% cells expressing the lamin fragment
(Fig. 2D). These results reaffirm that expression of wild-type p300 or
the E1A-binding p300 mutant is sufficient to rescue cells from
p53-mediated apoptosis.
|
To determine whether LTR.1A cells can be made susceptible to
p53-mediated death, we transiently transfected wild-type E1A (12S E1A)
into these cells. Transient expression of 12S E1A in LTR.1A cells (Fig.
2E) promoted apoptosis at the permissive temperature (Fig. 2F). In
addition, Mdm2 levels were down-regulated in cells transfected with 12S
E1A as detected by Western blot analysis (Fig. 2E). Because E1A can
also bind to Rb, we transiently transfected LTR.1A cells with 12S E1A
mutant (12S.RG2) that is unable to bind to p300 but retains it ability
to bind to Rb, and a 12S E1A mutant (12S.YH47.928) that binds to p300
but not to Rb (Wang et al. 1992
), and examined p53-dependent apoptosis
at the permissive temperature. Cells transfected with 12S.RG2 did not
down-regulate Mdm2 (Fig. 2E) and were resistant to p53-dependent
apoptosis (Fig. 2F). In contrast, cells transfected with 12S.YH47.928
down-regulated Mdm2 (Fig. 2E) and were susceptible to p53-dependent
apoptosis at the permissive temperature (Fig. 2F). These results
suggest that the ability of E1A to bind to p300 and inhibit Mdm2
induction correlates with E1A-mediated, p53-dependent apoptosis.
Overexpression of Mdm2 inhibits p53-mediated apoptosis
To determine whether Mdm2 expression can bypass
the requirement for p300 cotransactivation and rescue
p53A cells from p53-mediated death, we transiently
transfected p53A cells with expression plasmids encoding wild-type Mdm2 and a truncated form of Mdm2
lacking the amino-terminal p53-binding domain (Haupt et
al. 1997
). Transient overexpression of wild-type and
mutant Mdm2 were detected by Western blot analysis in
p53A cells (Fig. 3A). Transient
transfection of cells with 5 or 10 µg wild-type Mdm2
rescued cells from p53-dependent apoptosis at the permissive
temperature (Fig. 3B). The truncated form of Mdm2 rescued
cells from apoptosis less efficiently than the wild-type
protein (Fig. 3B), presumably because it was not able to bind to
p53 and promote its degradation. Furthermore, we examined the cell
morphology of p53A cells expressing a wild-type and mutant Mdm2 plasmid
DNA as compared to the morphology of cells expressing a control lamin
fragment incubated at the permissive temperature using indirect
immunofluorescence (Fig. 3C). The percentage of apoptotic cells
expressing wild-type and mutant Mdm2 was only 10% and 30%,
respectively, as compared to 56% apoptosis in cells expressing the
control lamin fragment (Fig. 3C). The Mdm2 mutant, however, possessed
greater apoptosis-suppressing activity than the control lamin fragment,
which may indicate that Mdm2 can suppress apoptosis by a mechanism
independent of p53 binding. These results demonstrate that
overexpression of Mdm2 can rescue E1A-expressing cells from
p53-mediated apoptosis by either promoting p53 degradation or by
inhibiting its activity by direct interaction.
|
E1B 19K or Bcl-2 can bypass E1A inhibition of p300 and restore mdm2 transactivation
Another mechanism for suppressing p53-dependent apoptosis is through expression of Bcl-2 or E1B 19K, which function in part by binding to Bax and inactivating its pro-apoptotic function. To test if Bcl-2 or E1B 19K could also function to suppress apoptosis by influencing p53 target gene expression, we examined p53-inducible gene products, Mdm2, p21WAF1, and Bax, in p53A cells stably expressing adenovirus E1B 19K (19K1) or its human homolog Bcl-2 (4B).
As reported previously, the expression of 19K or Bcl-2 abrogates
p53-dependent apoptosis at 32°C (Chiou et al. 1994a
; Sabbatini et
al. 1995a
; Han et al. 1996
). Western blot analysis indicated that
p21WAF1 and Bax levels increased at 32°C regardless of
whether or not 19K or Bcl-2 were expressed and the levels of p53
remained high (Fig. 4A). However, the presence of 19K
or Bcl-2 dramatically up-regulated Mdm2 levels, whereas the control
E1A + tsp53 (val135)-transformed p53A cells transfected with
vector alone (p53An1) down-regulated Mdm2 as expected (Fig. 4A). This
suggested that E1B 19K or Bcl-2 could restore p53-dependent
mdm2 expression in p53A cells.
|
To determine whether the expression of E1B 19K or Bcl-2 was sufficient for up-regulation of Mdm2 levels, we transiently transfected 19K or Bcl-2 in p53An1 cells and examined Mdm2 levels at 32°C. Western blot analysis (Fig. 4B) and indirect immunofluorescence (data not shown) indicated that Mdm2 levels were up-regulated when either 19K or Bcl-2 was expressed transiently.
To determine whether the expression of E1B 19K up-regulates Mdm2 at the
transcriptional level, we performed Northern blot analysis using
cytoplasmic RNA from cells expressing E1B 19K (19K1) incubated at
32°C for the indicated time intervals (Fig. 4C). As shown in Fig.
4C, mdm2 mRNA expression was up-regulated after 48 hr
incubation at permissive temperature. This suggested that E1B 19K and
Bcl-2 may restore mdm2 transactivation by p53, which would
otherwise be inhibited by E1A binding to p300. In addition, previous
studies have shown that Bax and p21WAF1
mRNA and protein were also up-regulated in 19K1 cells incubated at the
permissive temperature (Sabbatini et al. 1995a
,b
; Han et al. 1996
).
Therefore the presence of 19K did not affect the expression of
Bax or p21WAF1, however, E1B 19K can
directly bind to Bax and inhibit its function (Han et al. 1996
). E1B
19K and Bcl-2 have been shown to relieve transcriptional repression by
E1A and p53, which may be responsible for inhibition of apoptosis (Shen
and Shenk 1994
; Sabbatini et al. 1995a
; Murphy et al. 1996
) and Mdm2
may be a physiological target of this activity.
| |
Discussion |
|---|
|
|
|---|
E1A + tsp53 (val135)-transformed p53A cells were unable to
transactivate mdm2 as a result of E1A inhibition of p300,
indicating that p53 requires p300 to transactivate mdm2 (Fig
5). Furthermore, low Mdm2 levels in p53A cells
relieve the negative-feedback regulation of p53 resulting in high p53
accumulation leading to apoptosis. In contrast, p300 function is intact
and able to transactivate mdm2 with p53 in c-Myc + tsp53
(val135)-transformed LTR.1A cells (Fig. 5). Up-regulation of
mdm2 inhibits p53 function and promotes p53 degradation (Haupt
et al. 1997
; Kubbutat et al. 1997
), which in turn inhibits p53-mediated
cell death resulting in growth arrest in LTR.1A cells. The cellular
levels of p53 thereby control the biological response to p53 such that
lower levels of p53 induce growth arrest, whereas higher levels induce
apoptosis (Chen et al. 1996b
). Therefore, we can conclude that p300
regulation of Mdm2 levels determines whether the physiological response
to p53 is growth arrest or apoptosis. Curiously, the expression of the 19K or Bcl-2 proteins in p53A cells (19K1, 4B) bypasses the requirement for p300 in mdm2 transactivation (Fig. 5). Thus, prosurvival
members of the Bcl-2 family can inhibit p53-dependent apoptosis by
restoring the capacity of p53 to transactivate mdm2.
|
Interestingly, p300 cotransactivation is not required for the other
p53-inducible genes, Bax and p21WAF1. It
has been reported previously that E1A inhibits p53-mediated transactivation using promoter reporter assays (Steegenga et al. 1996
).
Our studies, however, demonstrate that E1A specifically inhibits
endogenous mdm2 transactivation and not other p53-inducible genes such as bax and p21WAF1.
p300/CBP functions by interacting not only with p53, but
also with other factors such as the TAFs (Thut et al. 1995
), TBP
(Abraham et al. 1993
), CREB (Chrivia et al. 1993
; Kwok et al. 1994
),
c-Jun/v-Jun (Bannister and Kouzarides 1995
),
c-Myb/v-Myb (Dai et al. 1996
), c-Fos (Bannister and
Kouzarides 1995
), and others. p300 binding to p53 alone may not
regulate the specificity of cotransactivation. However, as numerous
other protein interactions with p300 occur, this may determine the
specificity of transactivation, accounting for differential regulation
of p53-inducible genes by p300.
p300/CBP transcriptional coactivators have been shown to
have histone acetyltransferase activity, which can modify chromatin structure and enhance gene expression (Bannister and Kouzarides 1996
;
Ogryzko et al. 1996
). Recently, p300 has been shown to acetylate p53
itself (Gu and Roeder 1997
). The acetylation of p53 increases the
binding activity of p53 to specific consensus sequences. In vivo, this
activity may be required for facilitating p53 tetramer interactions
with the DNA template, thereby promoting mdm2 transactivation. However, acetylation of p53 by p300 may not be the only regulatory mechanism to control transactivation of p53-inducible genes. Gene transactivation may also depend on interactions with activators as well
as coactivators at the promoter site to initiate transcription. Hence,
different levels of regulation may play a role in transactivation of
p53-inducible genes.
Mutations that inactivate p300 have been described in colorectal and
gastric carcinomas (Muraoka et al. 1996
), which may suggest that p300
functions as a negative regulator of cell growth. Misense mutations of
p300, coupled to the deletion of the second allele of the gene, was
observed in these carcinomas (Muraoka et al. 1996
). Gene mutations were
found in the Cys/His-rich regions of p300, which are
known to play an important role in p300 function. These observations
suggests that inactivation of p300 may play a role in the development
of carcinomas. E1A inhibition of p300 transactivation may be one
mechanism whereby this viral protein promotes cellular transformation.
Interestingly, E1A binds Cys/His-rich region 3 thereby
inactivating p300's function (Eckner et al. 1994
). Moreover, p300
inactivation may render cells susceptible to agents that induce
p53-mediated cell death such as UV and ionizing radiation. It is
intriguing to speculate that acetyltransferase inhibitors specific for
p300 may be used in cells that do not respond to chemotherapy
regardless of having wild-type p53.
Finally, E1B 19K and Bcl-2 can bypass E1A inhibition of p300 function
and restore mdm2 transactivation, thereby inhibiting p53-dependent apoptosis. The up-regulation of mdm2 expression by E1B 19K and Bcl-2 may occur by alleviating the repressive function of adenovirus E1A protein caused by p300 inhibition. These results suggest that members of the anti-apoptotic family may promote survival
by bypassing the requirement for p300 function. Both E1B 19K and Bcl-2
have been shown to relieve transcriptional repression by E1A and p53
(Yoshida et al. 1987
; Shen and Shenk 1994
; Sabbatini et al. 1995a
). In
addition, E1B 19K can block repression by E1A caused by p300 inhibition
(Yoshida et al. 1987
; Stein et al. 1991
; Lee et al. 1995
). We cannot
rule out the possibility that E1B 19K and Bcl-2 might up-regulate a
p300-like activity that can then co-operate with p53 to transactivate
the mdm2 gene. Hence, E1B 19K and Bcl-2 may promote survival,
not only by binding and inhibiting Bax, but also by relieving
transcriptional repression or by enhancing transcription.
| |
Materials and methods |
|---|
|
|
|---|
Cells and culture conditions
Primary Fisher BRK cells were prepared from 6-day-old baby rats
and cultured in Dulbecco's modified Eagle medium (DMEM) with 10%
fetal bovine serum as described previously (White et al. 1991
). Plasmids were transfected by electroporation, and cells were maintained in DMEM with 10% fetal bovine serum. The transformed BRK cell line,
p53A, was derived from transfection of pCMVE1A and pLTRcGval135 plasmids (Debbas and White 1993
). The 19K1 and 4B cell lines were derived from transfecting pCMV19K and pSVBcl-2, respectively, and a
neomycin-resistance plasmid, pSVneo, by electroporation (Debbas and
White 1993
; Chiou et al. 1994a
; Sabbatini et al. 1995a
). Control cell
line p53An1 was derived from p53A cells containing only the
neomycin-resistance plasmid (Debbas and White 1993
). The LTR.1A cells
were generated by transfecting primary BRK cells with 10 µg of LTR
H-myc, which expresses human c-Myc, and pLTRcGval135 as described
previously (Sakamuro et al. 1995
).
Antibodies
SMP14, a mouse monoclonal anti-Mdm2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used at 1:1000 (Western) or 1:100 (immunofluorescence) to detect Mdm2. PAb248, a murine-specific anti-p53 mouse monoclonal antibody which was kindly provided by A. Levine was used at 1:5000 to detect p53. Mouse monoclonal anti-p21WAF1 (Ab-4, Calbiochem, San Diego, CA) was used at 1:50 dilution to detect p21WAF1. A rabbit polyclonal anti-Bax (P-19, Santa Cruz) was used at 1:100 to detect Bax and a mouse monoclonal anti-actin antibody (Amersham) was used at 1:1000 dilution to detect actin. Anti-HA mouse monoclonal antibody (Babco, Richmond, CA) at 1:1000 dilution was used to detect ectopically expressed p300 and a mouse monoclonal anti-E1A antibody M73 (Calbiochem) was used at 1:1000 dilution to detect E1A. A monoclonal anti-myc antibody (Calbiochem) was used at 1:1000 dilution to detect myc-tagged proteins, Bcl-2, and lamin mutant. A polyclonal anti-E1B 19K antibody was used at 1:10,000 to detect transiently expressed E1B 19K.
Cell viability and morphology
Cell viability was measured by trypan blue staining. Cells were trypsinized, centrifuged, resuspended in PBS, and counted using a hemocytometer after diluting in trypan blue. Apoptotic morphology was assessed by scoring for cells that are positive by fluorescence microscopy and are rounded and nonadherent. Cell morphology was also documented by photography at 100× magnification on a Nikon phase-contrast microscope and camera using Kodak film.
Western blot analysis
Cells were incubated at 37.5°C and 32°C for various time
intervals prior to lysing in buffer containing 4% SDS and 5%
-mercaptoethanol. Equal amounts of protein (20-30 µg) were
electrophoresed on 7.5%-12% SDS-PAGE gels and transferred to PVDF
membranes. Membranes were blocked for 15 min at room temperature in 5%
nonfat Carnation dry milk in PBS containing 0.1% Tween 20 (PBST).
Membranes were incubated with primary antibody followed by washes in
PBST and then incubated with horseradish peroxidase (HRP)-conjugated
sheep anti-mouse IgG or donkey anti-rabbit IgG monoclonal antibody at 1:2000 dilution. After several washes, blots were developed using the ECL chemiluminescence detection kit according to manufacturer's recommendations (Amersham Life Sciences, Arlington Heights, IL).
Indirect immunofluorescence and microscopy
Cells were fixed in cold methanol prior to incubation with primary antibodies. Subsequent to washes in PBS, cells were incubated with rhodamine-conjugated goat anti-mouse antibody or fluorescein-conjugated goat anti-rabbit antibody. Cells were then washed, mounted, and analyzed by fluorescence microscopy using a Nikon FXA epifluorescence microscope.
Northern blot analysis
Cytoplasmic RNA was extracted from p53A and 19K1 cells using the
NP-40 lysis protocol as described previously (Muraoka et al. 1996
).
Northern blots were done by loading 30 µg of cytoplasmic RNA on a
formaldehyde gel and blotted as described previously (Muraoka et al.
1996
) using Hybond-N membranes (Amersham) for transfer. The membrane
was hybridized with a random-primed labeled murine
mdm2-specific probe in ExpressHyb Hybridization solution (CloneTech, Palo Alto, CA) at 65°C. Blots were washed in 0.1× SSC
and 0.1% SDS at 50°C and exposed to film for 2 days.
Transient transfections
The indicated amount of plasmid DNA was transfected by
electroporation. After transfection, cells were incubated at 37.5°C for 24 hr to recover, and were then shifted to 32°C for 24 hr before
analysis for viability by trypan blue staining and apoptotic morphology. For p300 transfections, p53A cells were electroporated with
12 or 24 µg of pCMV
alone, pCMV
p300, or pCMVp300
30
mutant (deletion in E1A-interacting domain) (Arany et al. 1994
). For transient expression of E1A proteins, LTR.1A cells were electroporated with 10 µg of pCMV
alone, pCMV12SE1A, pCMV12S.RG2, or
pCMV12S.YH47.928 (Wang et al. 1992
). For Mdm2 transient expression,
p53A cells were electroporated with 5-10 µg of pCMV
alone,
pCOC-X2 (wild-type Mdm2), and pCOC-
XM (mutant Mdm2 with
deletion of the amino-terminal p53-binding domain) (Haupt et al. 1997
).
p53A cells were transfected transiently with 10 µg of
pCEP4-myc-LA(1-406) by electroporation to detect transient expression
of a lamin fragment as a control protein (Rao et al. 1996
). Transient
expression of Bcl-2 and E1B 19K was achieved by electroporating 10 µg of pCDNA3-Bcl-2 and pCMV19K plasmids into p53A cells.
| |
Acknowledgments |
|---|
We thank Moshe Oren for providing the mdm2 expression plasmids, Steve Grossman for the p300 expression plasmids, Elizabeth Moran for E1A mutant expression plasmids, and Arnold Levine for providing murine-specific anti-p53 antibody. This work was supported by National Institutes of Health grant CA-60088 to E.W.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| |
Footnotes |
|---|
Received December 29, 1997; revised version accepted May 4, 1998.
1 Corresponding author.
E-MAIL ewhite{at}mbcl.rutgers.edu; FAX (732) 235-5795.
| |
References |
|---|
|
|
|---|
converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis.
Cell Growth Differ.
8:
643-653[Abstract].